English
Back
Download
Log in to access Online Inquiry
Back to the Top

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
25K Views
Comment
Sign in to post a comment
    Just exploring the app to grow my money. Don't scold me if I'm copying u k 😂
    678
    Followers
    44
    Following
    2365
    Visitors
    Follow

    Market Insights

    Market Hot Picks Market Hot Picks
    Unlock Now

    Discussing

    Gold price hits new high! Safe havens in a turbulent market?
    🎙️Discussion 1. The spot gold price climbed to an all-time high, with numerous institutions raising their gold price forecasts, would you b Show More

    Reassessing Chinese Assets

    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.